Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.

Breitenbuecher F, von Pawel J, Sebastian M, Kortsik C, Ting S, Kasper S, Wohlschläger J, Worm K, Morresi-Hauf A, Schad A, Westerwick D, Wehler B, Werner M, Munzert G, Gaschler-Markefski B, Schmid KW, Schuler M.

Oncol Res Treat. 2017;40(7-8):435-439. doi: 10.1159/000475503. Epub 2017 Jun 20.

2.

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).

Awad MM, Chu QS, Gandhi L, Stephenson JJ, Govindan R, Bradford DS, Bonomi PD, Ellison DM, Eaton KD, Fritsch H, Munzert G, Johnson BE, Socinski MA.

Lung Cancer. 2017 Feb;104:126-130. doi: 10.1016/j.lungcan.2016.12.019. Epub 2016 Dec 30.

PMID:
28212994
3.

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.

Awada A, Dumez H, Aftimos PG, Costermans J, Bartholomeus S, Forceville K, Berghmans T, Meeus MA, Cescutti J, Munzert G, Pilz K, Liu D, Schöffski P.

Invest New Drugs. 2015 Jun;33(3):611-20. doi: 10.1007/s10637-015-0223-9. Epub 2015 Mar 22.

4.

A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.

Müller-Tidow C, Bug G, Lübbert M, Krämer A, Krauter J, Valent P, Nachbaur D, Berdel WE, Ottmann OG, Fritsch H, Munzert G, Garin-Chesa P, Fleischer F, Taube T, Döhner H.

Br J Haematol. 2013 Oct;163(2):214-22. doi: 10.1111/bjh.12518. Epub 2013 Aug 16.

PMID:
24033250
5.

The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study.

Vose JM, Friedberg JW, Waller EK, Cheson BD, Juvvigunta V, Fritsch H, Petit C, Munzert G, Younes A.

Leuk Lymphoma. 2013 Apr;54(4):708-13. doi: 10.3109/10428194.2012.729833. Epub 2012 Oct 4.

PMID:
22978685
6.

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.

Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM, Hollerbach S, Merger M, Munzert G, Fleischer F, Scheulen ME.

Br J Cancer. 2012 Jul 10;107(2):280-6. doi: 10.1038/bjc.2012.257. Epub 2012 Jun 14.

7.

A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.

Ellis PM, Chu QS, Leighl N, Laurie SA, Fritsch H, Gaschler-Markefski B, Gyorffy S, Munzert G.

Clin Lung Cancer. 2013 Jan;14(1):19-27. doi: 10.1016/j.cllc.2012.04.003. Epub 2012 Jun 1.

PMID:
22658814
8.

Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.

Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R, Trommeshauser D, Munzert G.

Curr Oncol. 2012 Feb;19(1):e28-35. doi: 10.3747/co.19.866.

9.

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.

Schöffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, Munzert G.

Eur J Cancer. 2012 Jan;48(2):179-86. doi: 10.1016/j.ejca.2011.11.001. Epub 2011 Nov 24.

PMID:
22119200
10.

Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor.

Soto E, Staab A, Doege C, Freiwald M, Munzert G, Trocóniz IF.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1517-27. doi: 10.1007/s00280-011-1647-3. Epub 2011 Apr 24.

PMID:
21516508
11.

Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed.

Soto E, Staab A, Freiwald M, Munzert G, Fritsch H, Döge C, Trocóniz IF.

Clin Pharmacol Ther. 2010 Nov;88(5):660-7. doi: 10.1038/clpt.2010.148. Epub 2010 Oct 6.

PMID:
20927084
12.

An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.

Hofheinz RD, Al-Batran SE, Hochhaus A, Jäger E, Reichardt VL, Fritsch H, Trommeshauser D, Munzert G.

Clin Cancer Res. 2010 Sep 15;16(18):4666-74. doi: 10.1158/1078-0432.CCR-10-0318. Epub 2010 Aug 3.

13.

The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.

Sebastian M, Reck M, Waller CF, Kortsik C, Frickhofen N, Schuler M, Fritsch H, Gaschler-Markefski B, Hanft G, Munzert G, von Pawel J.

J Thorac Oncol. 2010 Jul;5(7):1060-7. doi: 10.1097/JTO.0b013e3181d95dd4.

14.

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).

Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, Sleijfer S, Wolter P, Ray-Coquard I, Fontaine C, Munzert G, Fritsch H, Hanft G, Aerts C, Rapion J, Allgeier A, Bogaerts J, Lacombe D.

Eur J Cancer. 2010 Aug;46(12):2206-15. doi: 10.1016/j.ejca.2010.03.039. Epub 2010 May 13.

PMID:
20471824
15.

Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development.

Soto E, Staab A, Tillmann C, Trommeshauser D, Fritsch H, Munzert G, Trocóniz IF.

Cancer Chemother Pharmacol. 2010 Sep;66(4):785-95. doi: 10.1007/s00280-009-1223-2. Epub 2010 Jan 9.

PMID:
20062994
16.

An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma.

Kropff M, Kienast J, Bisping G, Berdel WE, Gaschler-Markefski B, Stopfer P, Stefanic M, Munzert G.

Anticancer Res. 2009 Oct;29(10):4233-8.

17.

Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.

Bisping G, Wenning D, Kropff M, Gustavus D, Müller-Tidow C, Stelljes M, Munzert G, Hilberg F, Roth GJ, Stefanic M, Volpert S, Mesters RM, Berdel WE, Kienast J.

Clin Cancer Res. 2009 Jan 15;15(2):520-31. doi: 10.1158/1078-0432.CCR-08-1612.

18.

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, Rouyrre N, Trommeshauser D, Hoesl CE, Munzert G.

J Clin Oncol. 2008 Dec 1;26(34):5511-7. doi: 10.1200/JCO.2008.16.1547. Epub 2008 Oct 27.

PMID:
18955456
19.

Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors.

Kulimova E, Oelmann E, Bisping G, Kienast J, Mesters RM, Schwäble J, Hilberg F, Roth GJ, Munzert G, Stefanic M, Steffen B, Brandts C, Müller-Tidow C, Kolkmeyer A, Büchner T, Serve H, Berdel WE.

Mol Cancer Ther. 2006 Dec;5(12):3105-12.

20.

Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.

Bisping G, Kropff M, Wenning D, Dreyer B, Bessonov S, Hilberg F, Roth GJ, Munzert G, Stefanic M, Stelljes M, Scheffold C, Müller-Tidow C, Liebisch P, Lang N, Tchinda J, Serve HL, Mesters RM, Berdel WE, Kienast J.

Blood. 2006 Mar 1;107(5):2079-89. Epub 2005 Nov 8.

PMID:
16278310
21.

CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.

Liebisch P, Eppinger S, Schöpflin C, Stehle G, Munzert G, Döhner H, Schmid M.

Haematologica. 2005 Apr;90(4):489-93.

22.

Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

Munzert G, Kirchner D, Ottmann O, Bergmann L, Schmid RM.

Leuk Lymphoma. 2004 Jun;45(6):1181-4.

PMID:
15359998
23.

CD44v6: a target for antibody-based cancer therapy.

Heider KH, Kuthan H, Stehle G, Munzert G.

Cancer Immunol Immunother. 2004 Jul;53(7):567-79. Epub 2004 Feb 5. Review.

PMID:
14762695
24.

Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.

Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ.

J Nucl Med. 2003 Oct;44(10):1690-9.

25.

Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.

Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G.

Exp Hematol. 2003 Jun;31(6):504-11.

PMID:
12829026
26.

3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease.

Wagner M, Seitz U, Buck A, Neumaier B, Schultheiss S, Bangerter M, Bommer M, Leithäuser F, Wawra E, Munzert G, Reske SN.

Cancer Res. 2003 May 15;63(10):2681-7.

27.

Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis.

Munzert G, Kirchner D, Stobbe H, Bergmann L, Schmid RM, Döhner H, Heimpel H.

Blood. 2002 Nov 15;100(10):3749-56.

PMID:
12411322
28.

Liposomal delivery of antisense oligonucleotides for efficient downregulation of Bcl-2 and induction of apoptosis.

Buck AC, Shen C, Schirrmeister H, Schmid-Kotsas A, Munzert G, Guhlmann A, Mehrke G, Klug N, Gross HJ, Bachem M, Reske SN.

Cancer Biother Radiopharm. 2002 Jun;17(3):281-9.

PMID:
12136520
29.

Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.

Gleissner B, Gökbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, Fonatsch C, Heyll A, Voliotis D, Beck J, Lipp T, Munzert G, Maurer J, Hoelzer D, Thiel E; German Multicenter Trials of Adult Acute Lymphoblastic Leukemia Study Group.

Blood. 2002 Mar 1;99(5):1536-43.

PMID:
11861265
30.

Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.

Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M, Dohr D, Stefanic M, Buck A, Harsdorf SV, Glatting G, Grimminger W, Karakas T, Munzert G, Döhner H, Bergmann L, Reske SN.

Blood. 2001 Aug 1;98(3):565-72.

PMID:
11468151
31.

Normal structure of NFKB2, C-REL and BCL-3 gene loci in lymphoproliferative and myeloproliferative disorders.

Munzert G, Kreitmeier S, Bergmann L.

Leuk Lymphoma. 2000 Jul;38(3-4):395-400.

PMID:
10830747
32.

The SH2-containing adapter protein GRB10 interacts with BCR-ABL.

Bai RY, Jahn T, Schrem S, Munzert G, Weidner KM, Wang JY, Duyster J.

Oncogene. 1998 Aug 27;17(8):941-8.

33.

Concomitant manifestation of systemic lupus erythematosus and low-grade non-Hodgkin's lymphoma.

Munzert G, Frickhofen N, Bauditz J, Schreiber S, Herrmann F.

Leukemia. 1997 Aug;11(8):1324-8.

34.

Construction of a novel bifunctional biogenic amine receptor by two point mutations of the H2-histamine receptor.

DelValle J, Gantz I, Wang L, Guo YJ, Munzert G, Tashiro T, Konda Y, Yamada T.

Mol Med. 1995 Mar;1(3):280-6.

35.

Localization of the genes encoding the melanocortin-2 (adrenocorticotropic hormone) and melanocortin-3 receptors to chromosomes 18p11.2 and 20q13.2-q13.3 by fluorescence in situ hybridization.

Gantz I, Tashiro T, Barcroft C, Konda Y, Shimoto Y, Miwa H, Glover T, Munzert G, Yamada T.

Genomics. 1993 Oct;18(1):166-7. No abstract available.

36.

Molecular cloning of a novel melanocortin receptor.

Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, Watson SJ, DelValle J, Yamada T.

J Biol Chem. 1993 Apr 15;268(11):8246-50.

37.

Molecular basis for the interaction of histamine with the histamine H2 receptor.

Gantz I, DelValle J, Wang LD, Tashiro T, Munzert G, Guo YJ, Konda Y, Yamada T.

J Biol Chem. 1992 Oct 15;267(29):20840-3.

38.

Molecular cloning of the human histamine H2 receptor.

Gantz I, Munzert G, Tashiro T, Schäffer M, Wang L, DelValle J, Yamada T.

Biochem Biophys Res Commun. 1991 Aug 15;178(3):1386-92.

39.

Vagally induced release of gastrin, somatostatin and bombesin-like immunoreactivity from perfused rat stomach. Effect of stimulation frequency and cholinergic mechanisms.

Madaus S, Bender H, Schusdziarra V, Kehe K, Munzert G, Weber G, Classen M.

Regul Pept. 1990 Oct 8;30(3):179-92.

PMID:
1979685

Supplemental Content

Loading ...
Support Center